Published in Clin Cancer Res on June 17, 2011
Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell (2012) 2.34
Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res (2012) 2.24
A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages. Nat Cell Biol (2014) 2.01
Arsenic-transformed malignant prostate epithelia can convert noncontiguous normal stem cells into an oncogenic phenotype. Environ Health Perspect (2012) 1.66
The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis. Neoplasia (2013) 1.58
Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. Gastroenterology (2014) 1.35
Normal breast tissue of obese women is enriched for macrophage markers and macrophage-associated gene expression. Breast Cancer Res Treat (2011) 1.24
Metaplastic breast carcinomas are enriched in markers of tumor-initiating cells and epithelial to mesenchymal transition. Mod Pathol (2011) 1.18
The IL-8/CXCR1 axis is associated with cancer stem cell-like properties and correlates with clinical prognosis in human pancreatic cancer cases. Sci Rep (2014) 1.04
Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures. PLoS One (2011) 1.03
A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model. Breast Cancer Res (2013) 1.02
Circulating tumor cells in the diagnosis and management of pancreatic cancer. Biochim Biophys Acta (2012) 1.02
Epithelial-mesenchymal plasticity of breast cancer stem cells: implications for metastasis and therapeutic resistance. Curr Pharm Des (2015) 1.01
Complex role for the immune system in initiation and progression of pancreatic cancer. World J Gastroenterol (2014) 1.00
The role of high mobility group box 1 in innate immunity. Yonsei Med J (2014) 1.00
SNAI1-mediated epithelial-mesenchymal transition confers chemoresistance and cellular plasticity by regulating genes involved in cell death and stem cell maintenance. PLoS One (2013) 1.00
Cancer stem cell and stromal microenvironment. Ochsner J (2013) 0.98
Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Res (2014) 0.98
Increased circulation of galectin-3 in cancer induces secretion of metastasis-promoting cytokines from blood vascular endothelium. Clin Cancer Res (2013) 0.97
Concise Review: Targeting Cancer Stem Cells Using Immunologic Approaches. Stem Cells (2015) 0.97
Multiple regulation pathways and pivotal biological functions of STAT3 in cancer. Sci Rep (2015) 0.96
SCCA1/SERPINB3 promotes oncogenesis and epithelial-mesenchymal transition via the unfolded protein response and IL6 signaling. Cancer Res (2014) 0.93
Epigenetic silencing of microRNA-149 in cancer-associated fibroblasts mediates prostaglandin E2/interleukin-6 signaling in the tumor microenvironment. Cell Res (2015) 0.93
Co-expression of HER2 and HER3 receptor tyrosine kinases enhances invasion of breast cells via stimulation of interleukin-8 autocrine secretion. Breast Cancer Res (2012) 0.93
New Findings on Breast Cancer Stem Cells: A Review. J Breast Cancer (2015) 0.92
Bioengineered implantable scaffolds as a tool to study stromal-derived factors in metastatic cancer models. Cancer Res (2014) 0.92
Small-molecule inhibitors of acetyltransferase p300 identified by high-throughput screening are potent anticancer agents. Mol Cancer Ther (2013) 0.92
Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies. Oncogene (2015) 0.92
A flexible reporter system for direct observation and isolation of cancer stem cells. Stem Cell Reports (2014) 0.91
Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations. Adv Pharmacol (2012) 0.89
The colon cancer stem cell microenvironment holds keys to future cancer therapy. J Gastrointest Surg (2014) 0.88
A multi-targeted approach to suppress tumor-promoting inflammation. Semin Cancer Biol (2015) 0.87
Cancer Stem Cell Plasticity Drives Therapeutic Resistance. Cancers (Basel) (2016) 0.86
IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel. Nat Commun (2015) 0.86
Deficiency of C-C chemokine receptor 5 suppresses tumor development via inactivation of NF-κB and upregulation of IL-1Ra in melanoma model. PLoS One (2012) 0.86
Gastric stem cells and gastric cancer stem cells. Anat Cell Biol (2013) 0.86
Prognostic significance of interleukin-8 and CD163-positive cell-infiltration in tumor tissues in patients with oral squamous cell carcinoma. PLoS One (2014) 0.85
EGFR inhibitors prevent induction of cancer stem-like cells in esophageal squamous cell carcinoma by suppressing epithelial-mesenchymal transition. Cancer Biol Ther (2015) 0.84
Oxidative stress specifically downregulates survivin to promote breast tumour formation. Br J Cancer (2013) 0.83
Single-cell protein secretomic signatures as potential correlates to tumor cell lineage evolution and cell-cell interaction. Front Oncol (2013) 0.83
Translational horizons in the tumor microenvironment: harnessing breakthroughs and targeting cures. Med Res Rev (2015) 0.83
Cancer Stem Cells and Macrophages: Implications in Tumor Biology and Therapeutic Strategies. Mediators Inflamm (2016) 0.83
Modeling of Cancer Stem Cell State Transitions Predicts Therapeutic Response. PLoS One (2015) 0.82
Endogenous molecular network reveals two mechanisms of heterogeneity within gastric cancer. Oncotarget (2015) 0.82
Biological and clinical significance of cancer stem cell plasticity. Clin Transl Med (2014) 0.82
The NF-κB Pathway and Cancer Stem Cells. Cells (2016) 0.82
Inverse relationship between PSA and IL-8 in prostate cancer: an insight into a NF-κB-mediated mechanism. PLoS One (2012) 0.82
Stem cell niche dynamics: from homeostasis to carcinogenesis. Stem Cells Int (2012) 0.81
Gastroesophageal reflux activates the NF-κB pathway and impairs esophageal barrier function in mice. Am J Physiol Gastrointest Liver Physiol (2013) 0.80
Transcriptional shift identifies a set of genes driving breast cancer chemoresistance. PLoS One (2013) 0.80
Senescence-Inflammatory Regulation of Reparative Cellular Reprogramming in Aging and Cancer. Front Cell Dev Biol (2017) 0.80
Head and Neck Cancer Stem Cells: From Identification to Tumor Immune Network. J Dent Res (2015) 0.78
Overexpression of NRG1 promotes progression of gastric cancer by regulating the self-renewal of cancer stem cells. J Gastroenterol (2014) 0.78
ARTD1 Suppresses Interleukin 6 Expression by Repressing MLL1-Dependent Histone H3 Trimethylation. Mol Cell Biol (2015) 0.78
ΔNP63α transcriptionally activates chemokine receptor 4 (CXCR4) expression to regulate breast cancer stem cell activity and chemotaxis. Mol Cancer Ther (2014) 0.77
Tumor-associated macrophages: implications in cancer immunotherapy. Immunotherapy (2017) 0.76
Nanomedicine-Mediated Therapies to Target Breast Cancer Stem Cells. Front Pharmacol (2016) 0.76
Novel Biomarker Candidates for Colorectal Cancer Metastasis: A Meta-analysis of In Vitro Studies. Cancer Inform (2016) 0.75
Activation of Inflammatory Responses Correlate With Hedgehog Activation and Precede Expansion of Cancer Stem-Like Cells in an Animal Model of Residual Triple Negative Breast Cancer after Neoadjuvant Chemotherapy. Cancer Stud Mol Med (2015) 0.75
SOD2 and the Mitochondrial UPR: Partners Regulating Cellular Phenotypic Transitions. Trends Biochem Sci (2016) 0.75
Integrin-linked kinase as a novel molecular switch of the IL-6-NF-κB signaling loop in breast cancer. Carcinogenesis (2016) 0.75
Interplay between Inflammation and Stemness in Cancer Cells: The Role of Toll-Like Receptor Signaling. J Immunol Res (2016) 0.75
Targeting the Notch signaling pathway in cancer therapeutics. Thorac Cancer (2014) 0.75
Metastasis regulation by PPARD expression in cancer cells. JCI Insight (2017) 0.75
A class of genes in the HER2 regulon that is poised for transcription in breast cancer cell lines and expressed in human breast tumors. Oncotarget (2015) 0.75
CSCdb: a cancer stem cells portal for markers, related genes and functional information. Database (Oxford) (2016) 0.75
Autocrine interleukin-23 promotes self-renewal of CD133+ ovarian cancer stem-like cells. Oncotarget (2016) 0.75
Tumor-infiltrating macrophages, cancer stem cells and therapeutic responses. Oncotarget (2012) 0.75
CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer. World J Surg Oncol (2017) 0.75
Expression of HER2 in Breast Cancer Promotes a Massive Reorganization of Gene Activity and Suggests a Role for Epigenetic Regulation. J Data Mining Genomics Proteomics (2012) 0.75
Role of a polyphenol-enriched preparation on chemoprevention of mammary carcinoma through cancer stem cells and inflammatory pathways modulation. J Transl Med (2016) 0.75
The Crosstalk between Ovarian Cancer Stem Cell Niche and the Tumor Microenvironment. Stem Cells Int (2017) 0.75
Microbial infection, inflammation and epithelial ovarian cancer. Oncol Lett (2017) 0.75
Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells. J Vis Exp (2017) 0.75
The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling. Oncogenesis (2017) 0.75
An autocrine inflammatory forward-feedback loop after chemotherapy withdrawal facilitates the repopulation of drug-resistant breast cancer cells. Cell Death Dis (2017) 0.75
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
Identification and expansion of human colon-cancer-initiating cells. Nature (2006) 24.44
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell (2007) 22.89
The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer (2003) 22.78
STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer (2009) 15.45
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature (2007) 15.20
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
A perivascular niche for brain tumor stem cells. Cancer Cell (2007) 11.55
An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell (2009) 10.09
Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer (2005) 10.06
Cancer stem cells: an old idea--a paradigm shift. Cancer Res (2006) 9.76
Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res (2006) 7.91
Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol (2010) 7.73
The interleukin-8 pathway in cancer. Clin Cancer Res (2008) 7.12
Potentiation of the T-lymphocyte response to mitogens. II. The cellular source of potentiating mediator(s). J Exp Med (1972) 6.47
STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell (2010) 5.67
Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res (2004) 5.60
Control of mammary stem cell function by steroid hormone signalling. Nature (2010) 5.38
IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest (2007) 4.71
Progesterone induces adult mammary stem cell expansion. Nature (2010) 4.69
CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest (2010) 4.22
Transcriptional regulation via the NF-kappaB signaling module. Oncogene (2006) 3.92
IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A (2003) 3.80
Does the immune system see tumors as foreign or self? Annu Rev Immunol (2001) 3.71
Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol (2009) 3.67
Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol (2009) 3.58
Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res (2009) 3.52
Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell (2011) 3.32
Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell (2009) 3.29
Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res (2011) 3.18
Co-evolution of tumor cells and their microenvironment. Trends Genet (2008) 3.08
Targeting breast cancer stem cells. J Clin Oncol (2010) 2.53
The NF-kappaB pathway. J Cell Sci (2005) 2.20
Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res (2004) 2.12
Interleukin-6 trans-signalling in chronic inflammation and cancer. Scand J Immunol (2006) 1.95
Selective targeting of cancer stem cells: a new concept in cancer therapeutics. BioDrugs (2007) 1.76
The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clin Cancer Res (2006) 1.68
Interleukin-6 and its receptor: from bench to bedside. Med Microbiol Immunol (2006) 1.65
Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res (2006) 1.52
The canonical NF-kappaB pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion. Cancer Res (2010) 1.44
The interleukin-1 family of cytokines and receptors in human breast cancer: implications for tumor progression. Int J Oncol (2003) 1.33
Interleukin-8 modulates growth and invasiveness of estrogen receptor-negative breast cancer cells. Int J Cancer (2007) 1.26
A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res (2009) 1.20
The ubiquitous interleukin-6: a time for reappraisal. Cardiovasc Diabetol (2010) 1.16
Steroid hormone levels during pregnancy and incidence of maternal breast cancer. Cancer Epidemiol Biomarkers Prev (2002) 1.05
The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis. Expert Opin Biol Ther (2008) 1.04
Inadequacy of the new Response Evaluation Criteria in Solid Tumors (RECIST) in patients with malignant pleural mesothelioma: report of four cases. Lung Cancer (2004) 0.89
Outstanding problems with response evaluation criteria in solid tumors (RECIST) in breast cancer. Breast Cancer (2002) 0.83
'Please, desist RECIST criteria in GIST, at least in me'. Onkologie (2008) 0.78
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell (2007) 22.89
In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev (2003) 20.77
Cancer stem cells: an old idea--a paradigm shift. Cancer Res (2006) 9.76
Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res (2009) 7.98
Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res (2006) 7.91
Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res (2009) 6.43
Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res (2004) 5.60
BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci U S A (2008) 4.79
Stem cells in normal breast development and breast cancer. Cell Prolif (2003) 4.47
Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res (2009) 4.47
CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest (2010) 4.22
Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol (2009) 3.67
Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A (2012) 3.21
Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res (2011) 3.18
Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab (2004) 3.10
Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res (2005) 3.05
Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol (2008) 2.87
Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck (2010) 2.76
Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest (2011) 2.62
Targeting breast cancer stem cells. J Clin Oncol (2010) 2.53
Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res (2011) 2.50
Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell (2012) 2.34
HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res (2013) 2.27
Survival of mammary stem cells in suspension culture: implications for stem cell biology and neoplasia. J Mammary Gland Biol Neoplasia (2005) 2.13
Cancer stem cells: a step toward the cure. J Clin Oncol (2008) 2.08
Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int J Cancer (2011) 2.05
Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer Res (2009) 2.04
Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin Cancer Res (2010) 1.96
Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets. Nat Nanotechnol (2013) 1.92
Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells. Cancer Res (2010) 1.88
Cancer stem cells and metastasis: lethal seeds. Clin Cancer Res (2006) 1.84
Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. J Clin Oncol (2011) 1.79
Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res Treat (2009) 1.77
Cancer stem cells in breast: current opinion and future challenges. Pathobiology (2008) 1.77
Selective targeting of cancer stem cells: a new concept in cancer therapeutics. BioDrugs (2007) 1.76
Targeting breast cancer stem cells. Mol Oncol (2010) 1.72
Stem cells in mammary development and carcinogenesis: implications for prevention and treatment. Stem Cell Rev (2005) 1.65
HER-2, notch, and breast cancer stem cells: targeting an axis of evil. Clin Cancer Res (2009) 1.59
Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle (2009) 1.56
HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells. Clin Cancer Res (2012) 1.47
Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clin Cancer Res (2013) 1.43
Point: cancer stem cells--the evidence accumulates. Clin Chem (2012) 1.43
Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res (2012) 1.39
An embryonic stem cell-like signature identifies poorly differentiated lung adenocarcinoma but not squamous cell carcinoma. Clin Cancer Res (2009) 1.38
MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells. PLoS Genet (2012) 1.38
Role of microRNAs in the regulation of breast cancer stem cells. J Mammary Gland Biol Neoplasia (2012) 1.25
Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clin Cancer Res (2013) 1.20
Ablation of breast cancer stem cells with radiation. Transl Oncol (2011) 1.15
HER2 and breast cancer stem cells: more than meets the eye. Cancer Res (2013) 1.14
Mammary stem cell number as a determinate of breast cancer risk. Breast Cancer Res (2007) 1.12
Colon cancer stem cells: implications for prevention and therapy. Trends Mol Med (2008) 1.12
Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. J Nutr Biochem (2011) 1.10
Distinct FAK activities determine progenitor and mammary stem cell characteristics. Cancer Res (2013) 1.04
Cancer stem cells: implications for cancer treatment and prevention. Cancer J (2007) 1.04
Cancer stem cell heterogeneity in hereditary breast cancer. Breast Cancer Res (2008) 1.04
Stem cells in normal development and cancer. Prog Mol Biol Transl Sci (2010) 0.98
The inhibitory effects of gossypol on human prostate cancer cells-PC3 are associated with transforming growth factor beta1 (TGFbeta1) signal transduction pathway. Anticancer Res (2004) 0.96
Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo. Clin Immunol (2013) 0.95
Getting to the root of BRCA1-deficient breast cancer. Cell Stem Cell (2009) 0.95
Endothelial interleukin-6 defines the tumorigenic potential of primary human cancer stem cells. Stem Cells (2014) 0.93
Cancer stem cells: nature versus nurture. Nat Cell Biol (2010) 0.92
New organizational and funds flow models for an academic cancer center. Acad Med (2004) 0.91
Conjugated linoleic acid induces apoptosis through estrogen receptor alpha in human breast tissue. BMC Cancer (2008) 0.91
Regulatory roles of miRNA in the human neural stem cell transformation to glioma stem cells. J Cell Biochem (2014) 0.91
Breast cancer stem cells: we've got them surrounded. Clin Cancer Res (2012) 0.90
Notch reporter activity in breast cancer cell lines identifies a subset of cells with stem cell activity. Mol Cancer Ther (2015) 0.89
Breast cancer stem cells-research opportunities utilizing mathematical modeling. Stem Cell Rev (2007) 0.88
A radial flow microfluidic device for ultra-high-throughput affinity-based isolation of circulating tumor cells. Small (2014) 0.88
Artemin stimulates radio- and chemo-resistance by promoting TWIST1-BCL-2-dependent cancer stem cell-like behavior in mammary carcinoma cells. J Biol Chem (2012) 0.88
Function and regulatory mechanisms of the candidate tumor suppressor receptor protein tyrosine phosphatase gamma (PTPRG) in breast cancer cells. Anticancer Res (2010) 0.88
Primary vocal cord aspergillosis caused by Aspergillus fumigatus and molecular identification of the isolate. Med Mycol (2008) 0.87
Lin28 and HER2: two stem cell regulators conspire to drive aggressive breast cancer. Cell Cycle (2012) 0.86
[The cancer stem cell: the breast cancer driver]. Med Sci (Paris) (2007) 0.85
Inflammation and autophagy conspire to promote tumor growth. Cell Cycle (2011) 0.84
Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells. Anticancer Res (2006) 0.84
CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer. Breast Cancer Res Treat (2015) 0.84
Breast cancer stem cells: current advances and clinical implications. Methods Mol Biol (2015) 0.83
Identification of single chain antibodies to breast cancer stem cells using phage display. Biotechnol Prog (2009) 0.82
Targeting cancer stem cells via dendritic-cell vaccination. Oncoimmunology (2012) 0.82
Stemming a tumor with a little miR. Nat Med (2011) 0.81
The thyroid cancer PAX8-PPARG fusion protein activates Wnt/TCF-responsive cells that have a transformed phenotype. Endocr Relat Cancer (2013) 0.81
Effects of gossypol on O2 consumption and CO2 production in human prostate cancer cells. Anticancer Res (2002) 0.79
Primary cultured human breast epithelial cells up-regulate protein disulfide isomerase in response to zeranol. Anticancer Res (2007) 0.79
Conjugated linoleic acid (CLA) modulates prostaglandin E2 (PGE2) signaling in canine mammary cells. Anticancer Res (2006) 0.79
Conjugated linoleic acid (CLA) up-regulates the estrogen-regulated cancer suppressor gene, protein tyrosine phosphatase gamma (PTPgama), in human breast cells. Anticancer Res (2006) 0.78
[Stem cells and epithelial cancers: the example of breast cancer]. Ann Pathol (2008) 0.78